Skip to Content

Saratoga Health & Biotechnology C SHPCX

Medalist Rating as of | See Saratoga Investment Hub
  • NAV / 1-Day Return 13.36  /  +1.91 %
  • Total Assets 11.7 Mil
  • Adj. Expense Ratio
    3.350%
  • Expense Ratio 3.350%
  • Distribution Fee Level High
  • Share Class Type Level Load
  • Category Health
  • Investment Style Large Blend
  • Min. Initial Investment 250
  • Status Open
  • TTM Yield
  • Turnover 58%

USD | NAV as of May 31, 2024 | 1-Day Return as of May 31, 2024, 10:18 PM GMT+0

Morningstar’s Analysis SHPCX

Will SHPCX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

Saratoga Health& Biotechnology C's Average People Pillar and Process Pillar ratings are n't enough to prevent other weaknesses from sending this strategy to a Morningstar Medalist Rating of Negative.

null Morningstar Manager Research

Morningstar Manager Research

Summary

Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the most expensive quintile among peers.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings SHPCX

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 42.4
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Regeneron Pharmaceuticals Inc

5.22 644,868
Healthcare

Cencora Inc

5.05 623,269
Healthcare

Amgen Inc

4.59 566,365
Healthcare

McKesson Corp

4.56 563,692
Healthcare

Tenet Healthcare Corp

4.10 506,946
Healthcare

The Cigna Group

4.03 497,933
Healthcare

Elevance Health Inc

3.81 470,834
Healthcare

Exelixis Inc

3.72 459,603
Healthcare

Cardinal Health Inc

3.69 455,209
Healthcare

Intuitive Surgical Inc

3.62 446,981
Healthcare